Dextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability.
Dextromethorphan (DM) is among the most widely used, non-narcotic antitussives, with a predictable safety profile. In 1981, a non-opioid, high-affinity brain recognition site for DM was discovered, and since then a unique neuropharmacological profile has emerged for this 'old' drug , suggesting novel applications. However, an extensive body of research for DM alone in treating various neurological conditions has been inconsistent. This may be largely due to its rapid first-pass metabolism. DM is currently being reintroduced as the active ingredient in a novel combination product in which low-dose quinidine is added to inhibit its breakdown, elevating blood levels of DM and increasing its likelihood of reaching neuronal targets . This has opened new possibilities for therapeutic use; the best evidence at present being for neurological disorders affecting emotional control.
Smith
Richard Alan
RA
Center for Neurologic Study, 9850 Genesee Ave, Suite 320, La Jolla, California 92037, USA. cns@cts.com
D000342:Affective Symptoms / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D001682:Biological Availability; D003915:Dextromethorphan / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination; D006801:Humans; D019964:Mood Disorders / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology; D011802:Quinidine / Q000008:administration & dosage* / Q000493:pharmacokinetics
D003915:Dextromethorphan; D011802:Quinidine